MARKET

BCYC

BCYC

Bicycle Therapeutics Limited
NASDAQ
5.28
+0.22
+4.35%
After Hours: 5.38 +0.1 +1.89% 17:06 04/15 EDT
OPEN
5.08
PREV CLOSE
5.06
HIGH
5.30
LOW
5.03
VOLUME
620.74K
TURNOVER
--
52 WEEK HIGH
9.55
52 WEEK LOW
4.240
MARKET CAP
368.05M
P/E (TTM)
-1.6706
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at BCYC last week (0406-0410)?
Weekly Report · 2d ago
Bicycle Therapeutics Is Maintained at Equal-Weight by Morgan Stanley
Dow Jones · 04/08 13:39
Bicycle Therapeutics Price Target Cut to $12.00/Share From $13.00 by Morgan Stanley
Dow Jones · 04/08 13:39
Morgan Stanley Maintains Equal-Weight on Bicycle Therapeutics, Lowers Price Target to $12
Benzinga · 04/08 13:29
Bicycle Therapeutics price target lowered to $12 from $13 at Morgan Stanley
TipRanks · 04/08 11:55
Top Executives Quietly Cash Out at Bicycle Therapeutics
TipRanks · 04/07 02:02
Bicycle Therapeutics COO Jennifer Scott Perry disposes of shares worth $6,803
Reuters · 04/06 22:30
Weekly Report: what happened at BCYC last week (0330-0403)?
Weekly Report · 04/06 09:11
More
About BCYC
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.

Webull offers Bicycle Therapeutics PLC (ADR) stock information, including NASDAQ: BCYC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCYC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BCYC stock methods without spending real money on the virtual paper trading platform.